The US Food and Drug Administration (FDA) has approved a new gene therapy called Kresladi (marnetegragene autotemcel) developed by Rocket Pharmaceuticals for treating leukocyte adhesion deficiency type I, a rare inherited blood disorder that weakens the immune system. This treatment helps the body produce healthy white blood cells.
Additionally, the FDA will hold a public meeting to gather opinions and feedback from experts and the public about the agency’s Commissioner’s National Strategy for Combating Antibiotic-Resistant Bacteria. This strategy aims to address the growing problem of antibiotic-resistant infections by improving the development of new antibiotics and promoting their responsible use.
In other news, pharmaceutical company MSD has agreed to acquire Terns Pharmaceuticals, a company focused on cancer treatments, for $6.7 billion. This acquisition is part of MSD’s ongoing efforts to expand its portfolio in the fight against cancer through high-value drug developments.
Meanwhile, the FDA has also approved a new treatment from Johnson & Johnson called Icotyde (icotrokinra) for plaque psoriasis, a chronic skin condition causing red, scaly patches. This medication works by targeting specific proteins involved in the immune response that contribute to the disease.
In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) are collaborating to improve access to certain medicines. Their goal is to ensure that new and existing treatments are available to patients more quickly and efficiently, particularly for those with unmet medical needs.
GSK, a global healthcare company, has offered to support UK health authorities in managing an ongoing outbreak of meningococcal disease in Kent, England. Meningococcal disease is a serious bacterial infection that can lead to meningitis and sepsis, and public health responses often include vaccination campaigns to protect those at risk.
In the US, the ongoing changes to vaccine policies led by Health Secretary Robert F. Kennedy Jr. have faced delays. These changes aim to reform how vaccines are regulated and distributed in the country, but the process has encountered challenges in implementation.
In London, most patients taking medications for weight loss are paying for these treatments privately. This is because the rollout of such medications through the National Health Service (NHS) has been slow, leaving many people to seek these treatments through private healthcare providers instead.
The World Health Organization (WHO) has identified key characteristics that new antibacterial drugs should have to effectively treat three high-priority infections. These guidelines are part of a global effort to encourage the development of more effective antibiotics to combat the rise of resistant bacteria.
Eli Lilly, a major pharmaceutical company, has issued a warning about high levels of an impurity called NDMA in some versions of its popular diabetes and weight loss drug, which are prepared by compounding pharmacies. NDMA is a chemical that can be harmful in high amounts, and patients using these compounded versions are advised to consult their healthcare provider for guidance.